External Source

Leader: Ribociclib Plus Endocrine Therapy Reduces Ctdna In High-risk Er+/her2- Early Breast Cancer

2025 2:23

Arielle Medford, MD, Massachusetts General Cancer Center, Boston, MA, shares findings from the LEADER trial (NCT03285412), ...

Choose a download method below. All links open in new tabs.

Service	Features	Action
SaveFrom	MP4 & MP3 • HD Quality • Browser Extension Available	Download

Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.